scispace - formally typeset
R

Rebekka Hueting

Researcher at University of Oxford

Publications -  21
Citations -  587

Rebekka Hueting is an academic researcher from University of Oxford. The author has contributed to research in topics: In vivo & Olaparib. The author has an hindex of 12, co-authored 18 publications receiving 480 citations. Previous affiliations of Rebekka Hueting include St Thomas' Hospital.

Papers
More filters
Journal ArticleDOI

Metal complexes of thiosemicarbazones for imaging and therapy

TL;DR: In this paper, the coordination chemistry of thiosemicarbazone ligands with three (tridentate) or four (tetradentate) potential donor atoms is described.
Journal ArticleDOI

A comparison of the behavior of (64)Cu-acetate and (64)Cu-ATSM in vitro and in vivo

TL;DR: In vivo, in the EMT6 and CaNT tumors studied, the distribution of radiocopper from 64 Cu-ATSM in tumors essentially mirrors that of 64Cu-acetate suggests that copper metabolism may also play a role in the mechanism of selectivity of Cu- ATSM.
Journal ArticleDOI

PET Imaging of PARP Expression Using 18F-Olaparib

TL;DR: 18F-olaparib has great potential for noninvasive tumor imaging and monitoring of radiation damage and is accessed for the first time (to the authors' knowledge) via the copper-mediated 18F-radiofluorination of aryl boronic esters.
Journal ArticleDOI

Bis(thiosemicarbazones) as bifunctional chelators for the room temperature 64-copper labeling of peptides

TL;DR: In this paper, a range of carboxylate functionalised bis(thiosemicarbazone) ligands and their Cu(II) complexes have been prepared, fully characterised and radiolabeled in high yield with both 64Cu and 99mTc.
Journal ArticleDOI

In Vitro and In Vivo Evaluations of a Hydrophilic 64Cu-Bis(Thiosemicarbazonato)–Glucose Conjugate for Hypoxia Imaging

TL;DR: The in vitro cell uptake studies demonstrated that 64 Cu-ATSE/A-G retained hypoxia selectivity and had improved characteristics when compared with 64Cu-ATSM, and it was demonstrated that the method for the modification of Cu-bis(thiosemicarbazonato) complexes allows their biodistribution to be modified without negating their hypoxIA selectivity or tumor uptake properties.